Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA says Cerebral Health makes unapproved claims

This article was originally published in The Tan Sheet

Executive Summary

Cerebral Health's marketing claims that Alzenia Anti-Aging Brain Formula, Memeron Memory Enhancer, Neurotine Amino Acid Brain Fuel, Synaptine Nootropic and Cognitive Enhancer, Synaptine Blue Brain Health Supplement and Synaptine Elite Maximum Strength Nootropic prevent or ease symptoms of Alzheimer's disease, Parkinson's disease, strokes, Down's syndrome and other mental ailments render the products unapproved new drugs. In a Jan. 7 warning letter to the Jupiter, Fla., firm, FDA says the products' ingredients are not generally recognized as safe and effective for the mentioned uses

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel